CD7 CAR-T Cells(Ruijin Hospital)(CD7 CAR-T Cells(Ruijin Hospital)) - 药物靶点：CD7_在研适应症：外周T细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

CAR-T

别名-

靶点

CD7

作用方式

调节剂

作用机制

CD7调节剂(T细胞抗原CD7调节剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

外周T细胞淋巴瘤

非在研适应症-

原研机构

上海交通大学医学院附属瑞金医院

在研机构

上海交通大学医学院附属瑞金医院

非在研机构-

最高研发阶段早期临床1期

首次获批日期-

最高研发阶段(中国)早期临床1期

特殊审评-

登录后查看时间轴

关联

2

项与 CD7 CAR-T Cells(Ruijin Hospital) 相关的临床试验

NCT05979792

/ Not yet recruiting早期临床1期IIT

Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma

Despite the use of monoclonal antibodies, checkpoint inhibitors, and bispecific T cell adapters (BiTE) Immunotherapies such as chimeric antigen receptor (CAR) T cells have completely changed the treatment methods of various cancers.
However, only limited responses were observed in T cell diseases, In CD30 positive PTCL and CTCL patients. The use of BV in and pembroluzimab (Programmed cell death receptor 1) in the treatment of ENKTL.
Although some promising results have been observed for (PD-1) inhibitors, these positive results are limited to specific subtypes of T cell diseases.
CAR T Cell therapy in recurrent/refractory B-cell malignant tumors is very successful, the Food and Drug Administration (FDA) has approved two CAR T Cell therapy for the treatment of this type of disease. However, using this technology to treat T-cell malignancies has always been difficult, mainly due to the lack of tumor specific surface antigens in cancerous T cells.
Therefore, our center plans to conduct a phase I clinical study of CAR-T to explore the possibility of bringing more treatment options and benefits to PTCL patients.

开始日期2023-09-01

申办/合作机构

上海交通大学医学院附属瑞金医院

ChiCTR2100043252

/ Recruiting早期临床1期

Fully human CD7 CART cells from related donors combined with allogeneic hematopoietic stem cell transplantation for the treatment of refractory/relapsed T lymphoblastic lymphoma/leukemia in adults: single-center, open, non-randomized, single-arm clinical trial

开始日期2021-01-27

申办/合作机构

北京高博博仁医院有限公司

100 项与 CD7 CAR-T Cells(Ruijin Hospital) 相关的临床结果

登录后查看更多信息

100 项与 CD7 CAR-T Cells(Ruijin Hospital) 相关的转化医学

登录后查看更多信息

100 项与 CD7 CAR-T Cells(Ruijin Hospital) 相关的专利（医药）

登录后查看更多信息

3

项与 CD7 CAR-T Cells(Ruijin Hospital) 相关的文献（医药）

2022-12-01·Biomarker Research

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma

Letter

作者: Yang, Lin ; Cui, Wei ; Wu, De-Pei ; Dai, Hai-Ping ; Meng, Hui-Min ; Tang, Xiao-Wen ; Cui, Qing-Ya ; Zhu, Wen-Juan ; Zhu, Min-Qing ; Zhu, Xia-Ming

AbstractPatients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets for chimeric antigen receptor modified T cell therapy (CART) due to its widely expression in almost all T-cell malignancies. Here we present the anti-CD7 CART therapy in a 11-year-old male with TP53 mutated relapsed/refractory ETP-ALL/LBL. The patient suffered second relapse after haploidentical hematopoietic stem cell transplantation, showing resistance to 4 lines salvage therapies including venetoclax. Nanobody derived CD7-CART cells were manufactured by co-transducing CAR-T cells with a CD7 protein expression blocker. 70.5% of blasts (CD7 expression: 92.6%) and extensive extramedullary disease (mediastinal mass, enlarged lymph nodes and spleen) were observed prior to CD7-CART-cell therapy. A total of 5 × 106/kg donor-derived CD7-CART-cells were infused. Hematological and extramedullary remission were both achieved, with persistence of CD7-CART-cells be detected until the last followup at 96th days after the infusion. Reversible adverse effects including grade 3 cytokine release syndrome and macrophage activation syndrome were observed. This case demonstrated that CD7-CART was a potent and safe salvage therapy in relapsed/refractory ETP-ALL/LBL patient with high tumor burden.Trial registration: ClinicalTrials. gov, NCT04785833, Registered on March 8, 2021, prospectively registered.

2022-04-01·Journal of Zhejiang University (Medical Sciences)

Progress on CAR-T cell therapy for hematological malignancies

Review

作者: Huang, Yue ; Hu, Yongxian ; Huang, He ; Hu, Kejia

Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for hematological malignancies, which have experienced the development of CD19 CAR-T cells for B lymphoblastic leukemia and lymphoma, B cell maturation antigen (BCMA) CAR-T cells for multiple myeloid, and more recently, the development of CD7 CAR-T cells for T cell malignancies. There are more obstacles for myeloid malignancies compared to other hematological malignancies in this field, thus concerning researches are in more diverse ways. In order to obtain more effective clinical CAR-T cells with lower side effects, scientists have developed multi-target CAR-T cells, universal CAR-T cells, as well as CAR-T cells, CAR-NK cells, CAR-iMac cells derived from induced pluripotent stem cells (iPSC) by genetic engineering. Chinese scientists have made significant contribution to the invention and manufacture of origin CAR-T cells and the establishment of an intact clinical research system. This review introduces the latest progress involving CAR-T cell therapy for hematological malignancies including B lymphoblastic malignancies, T lymphoblastic malignancies and myeloid malignancies, and also discuss the future developments including multi-target, universal and iPSC-derived CAR-related cell therapy.

Frontiers in Oncology

The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis

Review

作者: Sun, Rui ; Zhang, Xiaomei ; An, Yuxin ; Gao, Xuejin ; Zhao, Mingfeng ; Liu, Jile ; Guo, Shujing

IntroductionCD7 chimeric antigen receptor T-cell (CAR-T cell) therapy is an emerging method for treating hematological malignancies, and is another breakthrough in CAR-T cell therapy.MethodsThis study summarizes the currently published clinical research results on CD7 CAR-T cells and evaluates the safety and effectiveness of CD7 CAR-T cell therapy.ResultsAmong the 13 studies included in this study, a total of 200 patients received CD7 CAR-T cell therapy, including 88 patients who received autologous CAR-T cells, 112 patients who received donor derived CAR-T cells. 87% (80% -94%, I2=29.65%) of patients achieved complete remission. The incidence of cytokine release syndrome (CRS) was 94% (88% -98%, I2 =32.71%, p=0.12), while the incidence of severe CRS (grade ≥ 3) was 12% (5% -20%, I2=41.04%, p=0.06). As for the incidence of immune effector cell-associated neurotoxicity syndrome (ICANS), it is 4% (1% -7%, I2=0, p=0.72). Through analysis of the key clinical issues, we found that consolidation allogeneic hematopoietic stem cell transplantation (allo-HSCT) after CAR-T cell therapy can significantly improve survival and avoid recurrence. Therefore, we believe that the consolidation allo-HSCT after CD7 CAR-T cell therapy should be advocated. And patients who received CD7 CAR-T cell therapy without gene editing had significantly longer overall survival than those who received CD7 CAR-T cell therapy with gene editing. This suggests that gene edited CD7 CAR-T cells may pose some potential risks that limit the long-term survival of patients.ConclusionOur study confirms the efficacy and safety of CD7 CAR-T cells and provides research directions for the subsequent treatment.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=502896, identifier CRD42024502896.

100 项与 CD7 CAR-T Cells(Ruijin Hospital) 相关的药物交易

登录后查看更多信息